CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer-Reference-Cited by-同舟云学术

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Published:2018-06-04 Issue:9 Volume:23 Page:1079-1082
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gillison Maura L.¹,Blumenschein George¹,Fayette Jerome²,Guigay Joel³,Colevas A. Dimitrios⁴,Licitra Lisa⁵,Harrington Kevin J.⁶,Kasper Stefan⁷,Vokes Everett E.⁸,Even Caroline⁹,Worden Francis¹⁰,Saba Nabil F.¹¹,Iglesias Docampo Lara Carmen¹²,Haddad Robert¹³,Rordorf Tamara¹⁴,Kiyota Naomi¹⁵,Tahara Makoto¹⁶,Monga Manish¹⁷,Lynch Mark¹⁷,Li Li¹⁷,Ferris Robert L.¹⁸

Affiliation:

1. MD Anderson Cancer Center, Houston, Texas, USA

2. Centre Leon Berard, Lyon, France

3. Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice, France

4. Stanford University, Stanford, California, USA

5. Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

6. Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, United Kingdom

7. West German Cancer Center, University Hospital, Essen, Germany

8. University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA

9. Gustave Roussy, Villejuif Cedex, France

10. University of Michigan, Ann Arbor, Michigan, USA

11. Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

12. Hospital Universitario 12 de Octubre, Madrid, Spain

13. Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA

14. Universitätsspital Zurich, Zurich, Switzerland

15. Kobe University Hospital Cancer Center, Kobe, Japan

16. National Cancer Center Hospital East, Kashiwa, Japan

17. Bristol-Myers Squibb, Princeton, New Jersey, USA

18. University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Abstract

Abstract Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2017-0674

Reference10 articles.

1. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN);Zenda;Jpn J Clin Oncol,2007

2. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised phase 3 trial;Machiels;Lancet Oncol,2011

3. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy;Andrade;Curr Opin Oncol,2012

4. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: Long-term report of efficacy and toxicity;Nguyen-Tan;J Clin Oncol,2014

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in Head and Neck Cancer;Surgical Oncology Clinics of North America;2024-10

2. Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges;JCO Oncology Practice;2024-05-06

3. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab;Journal of Clinical Medicine;2024-04-23

4. Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement;Bulletin du Cancer;2024-04

5. Oral epithelial dysplasia with lymphocytic immune response: clinicopathological characterisation of 44 cases;Histopathology;2024-03-18